• Citer

Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials.

par Juul, Nicolai;Szallasi, Zoltan;Eklund, Aron C;Li, Qiyuan;Burrell, Rebecca A;Gerlinger, Marco;Valero, Vicente;Andreopoulou, Eleni;Esteva, Francisco J;Symmans, W Fraser;Desmedt, Christine ;Haibe-Kains, Benjamin ;Sotiriou, Christos ;Pusztai, Lajos;Swanton, Charles
Référence Lancet oncology, 11, 4, page (358-365)
Publication Publié, 2010-02

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials.
Auteur:	Juul, Nicolai; Szallasi, Zoltan; Eklund, Aron C; Li, Qiyuan; Burrell, Rebecca A; Gerlinger, Marco; Valero, Vicente; Andreopoulou, Eleni; Esteva, Francisco J; Symmans, W Fraser; Desmedt, Christine; Haibe-Kains, Benjamin; Sotiriou, Christos; Pusztai, Lajos; Swanton, Charles
Informations sur la publication:	Lancet oncology, 11, 4, page (358-365)
Statut de publication:	Publié, 2010-02
Sujet CREF:	Sciences bio-médicales et agricoles
Note générale:	JOURNAL ARTICLE
	SCOPUS: ar.j
Langue:	Autre
Identificateurs:	urn:issn:1470-2045
	info:doi/10.1016/S1470-2045(10)70018-8
	info:pii/S1470-2045(10)70018-8
	info:scp/77950341123
	info:pmid/20189874